Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

The Association of Black Cardiologists (ABC) Cardiovascular Implementation Study (CVIS): A Research Registry Integrating Social Determinants to Support Care for Underserved Patients.

Ofili EO, Schanberg LE, Hutchinson B, Sogade F, Fergus I, Duncan P, Hargrove J, Artis A, Onyekwere O, Batchelor W, Williams M, Oduwole A, Onwuanyi A, Ojutalayo F, Cross JA, Seto TB, Okafor H, Pemu P, Immergluck L, Foreman M, Mensah EA, Quarshie A, Mubasher M, Baker A, Ngare A, Dent A, Malouhi M, Tchounwou P, Lee J, Hayes T, Abdelrahim M, Sarpong D, Fernandez-Repollet E, Sodeke SO, Hernandez A, Thomas K, Dennos A, Smith D, Gbadebo D, Ajuluchikwu J, Kong BW, McCollough C, Weiler SR, Natter MD, Mandl KD, Murphy S.

Int J Environ Res Public Health. 2019 May 10;16(9). pii: E1631. doi: 10.3390/ijerph16091631.

2.

Abnormal pulmonary function and associated risk factors in children and adolescents with sickle cell anemia.

Arteta M, Campbell A, Nouraie M, Rana S, Onyekwere OC, Ensing G, Sable C, Dham N, Darbari D, Luchtman-Jones L, Kato GJ, Gladwin MT, Castro OL, Minniti CP, Gordeuk VR.

J Pediatr Hematol Oncol. 2014 Apr;36(3):185-9. doi: 10.1097/MPH.0000000000000011.

3.

Clinical correlates of acute pulmonary events in children and adolescents with sickle cell disease.

Paul R, Minniti CP, Nouraie M, Luchtman-Jones L, Campbell A, Rana S, Onyekwere O, Darbari DS, Ajayi O, Arteta M, Ensing G, Sable C, Dham N, Kato GJ, Gladwin MT, Castro OL, Gordeuk VR.

Eur J Haematol. 2013 Jul;91(1):62-8. doi: 10.1111/ejh.12118. Epub 2013 May 3.

4.

Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson.

Field JJ, Lin G, Okam MM, Majerus E, Keefer J, Onyekwere O, Ross A, Campigotto F, Neuberg D, Linden J, Nathan DG.

Blood. 2013 Apr 25;121(17):3329-34. doi: 10.1182/blood-2012-11-465963. Epub 2013 Feb 1.

5.

Sickle cell disease (SCD), iNKT cells, and regadenoson infusion.

Nathan DG, Field J, Lin G, Neuberg D, Majerus E, Onyekwere O, Keefer J, Okam M, Ross A, Linden J.

Trans Am Clin Climatol Assoc. 2012;123:312-7; discussion 317-8.

6.

Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE).

Styles L, Wager CG, Labotka RJ, Smith-Whitley K, Thompson AA, Lane PA, McMahon LE, Miller R, Roseff SD, Iyer RV, Hsu LL, Castro OL, Ataga KI, Onyekwere O, Okam M, Bellevue R, Miller ST; Sickle Cell Disease Clinical Research Network (SCDCRN).

Br J Haematol. 2012 Jun;157(5):627-36. doi: 10.1111/j.1365-2141.2012.09105.x. Epub 2012 Mar 30.

7.

Markers of severe vaso-occlusive painful episode frequency in children and adolescents with sickle cell anemia.

Darbari DS, Onyekwere O, Nouraie M, Minniti CP, Luchtman-Jones L, Rana S, Sable C, Ensing G, Dham N, Campbell A, Arteta M, Gladwin MT, Castro O, Taylor JG 6th, Kato GJ, Gordeuk V.

J Pediatr. 2012 Feb;160(2):286-90. doi: 10.1016/j.jpeds.2011.07.018. Epub 2011 Sep 3.

8.

Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity.

Machado RF, Barst RJ, Yovetich NA, Hassell KL, Kato GJ, Gordeuk VR, Gibbs JS, Little JA, Schraufnagel DE, Krishnamurti L, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Onyekwere O, Castro OL, Sachdev V, Waclawiw MA, Woolson R, Goldsmith JC, Gladwin MT; walk-PHaSST Investigators and Patients.

Blood. 2011 Jul 28;118(4):855-64. doi: 10.1182/blood-2010-09-306167. Epub 2011 Apr 28.

9.

Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial.

Gladwin MT, Kato GJ, Weiner D, Onyekwere OC, Dampier C, Hsu L, Hagar RW, Howard T, Nuss R, Okam MM, Tremonti CK, Berman B, Villella A, Krishnamurti L, Lanzkron S, Castro O, Gordeuk VR, Coles WA, Peters-Lawrence M, Nichols J, Hall MK, Hildesheim M, Blackwelder WC, Baldassarre J, Casella JF; DeNOVO Investigators.

JAMA. 2011 Mar 2;305(9):893-902. doi: 10.1001/jama.2011.235.

10.

Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease.

Gordeuk VR, Campbell A, Rana S, Nouraie M, Niu X, Minniti CP, Sable C, Darbari D, Dham N, Onyekwere O, Ammosova T, Nekhai S, Kato GJ, Gladwin MT, Castro OL.

Blood. 2009 Nov 19;114(21):4639-44. doi: 10.1182/blood-2009-04-218040. Epub 2009 Sep 1.

11.

Prospective echocardiography assessment of pulmonary hypertension and its potential etiologies in children with sickle cell disease.

Dham N, Ensing G, Minniti C, Campbell A, Arteta M, Rana S, Darbari D, Nouraie M, Onyekwere O, Lasota M, Kato GJ, Gladwin MT, Castro O, Gordeuk V, Sable C.

Am J Cardiol. 2009 Sep 1;104(5):713-20. doi: 10.1016/j.amjcard.2009.04.034. Epub 2009 Jun 24.

12.

Prospective evaluation of haemoglobin oxygen saturation at rest and after exercise in paediatric sickle cell disease patients.

Campbell A, Minniti CP, Nouraie M, Arteta M, Rana S, Onyekwere O, Sable C, Ensing G, Dham N, Luchtman-Jones L, Kato GJ, Gladwin MT, Castro OL, Gordeuk VR.

Br J Haematol. 2009 Nov;147(3):352-9. doi: 10.1111/j.1365-2141.2009.07854.x. Epub 2009 Aug 19.

13.

Ferritin and increased vs upper reference interval tibc saturation to identify increased iron stores in African Americans.

Onyekwere OC, Kamineni P, Johnson-Largent TN, Fadojutimi-Akinsiku M, Dawkins FW, Gordeuk VR.

Clin Chim Acta. 2009 Jul;405(1-2):71-5. doi: 10.1016/j.cca.2009.04.001. Epub 2009 Apr 9.

PMID:
19362082
14.

Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation.

Minniti CP, Sable C, Campbell A, Rana S, Ensing G, Dham N, Onyekwere O, Nouraie M, Kato GJ, Gladwin MT, Castro OL, Gordeuk VR.

Haematologica. 2009 Mar;94(3):340-7. doi: 10.3324/haematol.13812. Epub 2009 Feb 11.

15.

High-density SNP genotyping to define beta-globin locus haplotypes.

Liu L, Muralidhar S, Singh M, Sylvan C, Kalra IS, Quinn CT, Onyekwere OC, Pace BS.

Blood Cells Mol Dis. 2009 Jan-Feb;42(1):16-24. doi: 10.1016/j.bcmd.2008.07.002. Epub 2008 Oct 1.

16.

l-selectin gene polymorphisms and complications of sickle cell disease.

Ugochukwu CC, Okpala I, Pantelidis P, Inusa B, Ibegbulam O, Onyekwere O.

Int J Lab Hematol. 2008 Aug;30(4):312-6. doi: 10.1111/j.1751-553X.2007.00961.x.

PMID:
18665829
17.

Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.

Vichinsky E, Pakbaz Z, Onyekwere O, Porter J, Swerdlow P, Coates T, Lane P, Files B, Mueller BU, Coïc L, Forni GL, Fischer R, Marks P, Rofail D, Abetz L, Baladi JF.

Acta Haematol. 2008;119(3):133-41. doi: 10.1159/000125550. Epub 2008 Apr 11.

PMID:
18408362
18.

Pulmonary hypertension in children and adolescents with sickle cell disease.

Onyekwere OC, Campbell A, Teshome M, Onyeagoro S, Sylvan C, Akintilo A, Hutchinson S, Ensing G, Gaskin P, Kato G, Rana S, Kwagyan J, Gordeuk V, Williams J, Castro O.

Pediatr Cardiol. 2008 Mar;29(2):309-12. Epub 2007 Aug 7.

PMID:
17680298
19.

Pulmonary hypertension in sickle cell disease: relevance to children.

Kato GJ, Onyekwere OC, Gladwin MT.

Pediatr Hematol Oncol. 2007 Apr-May;24(3):159-70. Review.

20.

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.

Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL, Okpala I, Ressayre-Djaffer C, Alberti D, Holland J, Marks P, Fung E, Fischer R, Mueller BU, Coates T; Deferasirox in Sickle Cell Investigators.

Br J Haematol. 2007 Feb;136(3):501-8.

21.

Self-perceived loss of control and untreated dental decay in African American adults with and without sickle cell disease.

Laurence B, Woods D, George D, Onyekwere O, Katz R, Lanzkron S, Diener-West M, Powe N.

J Health Care Poor Underserved. 2006 Aug;17(3):641-51.

PMID:
16960327
22.

Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene.

Gordeuk VR, Caleffi A, Corradini E, Ferrara F, Jones RA, Castro O, Onyekwere O, Kittles R, Pignatti E, Montosi G, Garuti C, Gangaidzo IT, Gomo ZA, Moyo VM, Rouault TA, MacPhail P, Pietrangelo A.

Blood Cells Mol Dis. 2003 Nov-Dec;31(3):299-304.

PMID:
14636642
23.

Neonatal alveolar rhabdomyosarcoma with skin and brain metastases.

Rodriguez-Galindo C, Hill DA, Onyekwere O, Pin N, Rao BN, Hoffer FA, Kun LE, Pappo AS, Santana VM.

Cancer. 2001 Sep 15;92(6):1613-20.

PMID:
11745240
24.

Selection of reagents for human radioimmunotherapy.

Vriesendorp HM, Quadri SM, Stinson RL, Onyekwere OC, Shao Y, Klein JL, Leichner PK, Williams JR.

Int J Radiat Oncol Biol Phys. 1992;22(1):37-45.

PMID:
1727128
25.

Participation of p53 protein in the cellular response to DNA damage.

Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW.

Cancer Res. 1991 Dec 1;51(23 Pt 1):6304-11.

26.

Levels of p53 protein increase with maturation in human hematopoietic cells.

Kastan MB, Radin AI, Kuerbitz SJ, Onyekwere O, Wolkow CA, Civin CI, Stone KD, Woo T, Ravindranath Y, Craig RW.

Cancer Res. 1991 Aug 15;51(16):4279-86.

27.

Factitious anisocoria and orthostatic hypotension.

Onyekwere OA, Morris H, Victor R, Fouad-Terazi FM.

Cleve Clin J Med. 1991 May-Jun;58(3):229-33. Erratum in: Cleve Clin J Med 1992 Jan-Feb;59(1):109.

Supplemental Content

Loading ...
Support Center